Immunohistochemical analysis of aldehyde dehydrogenase isoforms and their association with estrogen-receptor status and disease progression in breast cancer

Figures & data

Table 1 Patient demographics and isoform immunolabeling intensities

Tumor properties	ER+		TN		Total
	n	%	n	%	n	%
PR status
Positive	17	68	0	0	17	27
Negative	8	32	37	100	45	73
Stage
1A	2	8	4	11	6	19
1B	0	0	1	3	1	3
2A	12	48	12	32	24	80
2B	8	32	4	11	12	43
3A	2	8	4	11	6	19
3B	0	0	0	0	0	0
3C	1	4	5	14	6	18
4	0	0	2	5	2	5
Grade
1	4	18	0	0	4	7
2	11	50	7	20	18	32
3	7	32	28	80	35	61
Race
White/Caucasian	20	80	7	28	27	108
African American	3	12	20	80	23	92
Asian	2	8	0	0	2	8
Unknown	0	0	8	32	8	32
ALDH1A1
0	10	40	4	11	14	23
1	6	24	14	38	20	32
2	6	24	13	35	19	31
3	3	12	6	16	9	15
ALDH1A3
0	11	44	3	8	14	23
1	9	36	7	19	16	26
2	3	12	16	43	19	31
3	2	8	11	30	13	21

Abbreviations: ER+, estrogen-receptor positive; PR, progesterone receptor; TN, triple negative.

Table 2 Spearman’s correlation matrix

Tumor properties	Estrogen-receptor positive
	Grade	BMI	ALDH1A1	ALDH1A3	Stage
Grade		0.172	0.288	0.522	−0.024
P-value		0.455	0.194	0.013	0.916
BMI	0.154		−0.161	−0.112	0.204
P-value	0.583		0.474	0.621	0.362
OneA1	−0.176	−0.018		0.577	0.188
P-value	0.312	0.944		0.003	0.369
OneA3	−0.034	−0.284	0.264		0.384
P-value	0.847	0.27	0.114		0.058
Stage	0.211	−0.075	0.221	0.536
P-value	0.264	0.774	0.223	0.002
Triple negative

Note: Bold values indicate significance.

Abbreviation: BMI, body mass index.

Figure 1 Immunohistochemical analysis of ALDH1A1 and ALDH1A3 in breast-cancer specimens. Representative images are shown of negative, weak, moderate, and strong immunolabeling.

Note: Magnification is 20×.